Dexilant is expensive primarily because of its unique drug delivery technology, a dense wall of patents that has limited generic competition, and the fact that even available generics haven’t driven prices down as dramatically as patients expect. A 30-day supply of brand-name Dexilant runs around $309 without insurance, and the generic version (dexlansoprazole) can still cost $7 to $12 per capsule, far more than older acid reflux medications like omeprazole that sell for pennies per dose.
A Patent Strategy Built to Last
Takeda, the company behind Dexilant, has protected the drug with at least 15 patents listed in the FDA’s Orange Book. These patents don’t all expire at once. The earliest ones lapsed around 2020, but others extend through 2027, 2028, and the latest doesn’t expire until March 2032. Many of these patents also carry additional pediatric exclusivity extensions, which add six months of protection beyond the listed date.
This staggered approach is sometimes called a “patent thicket.” Each patent covers a different aspect of the drug: the active ingredient itself, the manufacturing process, the specific formulation. A generic manufacturer has to either wait for all relevant patents to expire or challenge them in court, which is costly and time-consuming. Par Pharmaceutical was the first generic applicant to file a challenge and received FDA approval, earning a 180-day period of exclusive generic marketing. But even with that approval in hand, the web of remaining patents has kept full-scale generic competition limited.
The Dual Release Technology
Dexilant isn’t just another proton pump inhibitor (PPI). It’s the only PPI with a dual delayed-release mechanism, and that technology is a big part of why it costs more and why its patents are harder to work around.
Each capsule contains two types of coated granules. One set dissolves in the upper small intestine, releasing the first dose of medication. The second set has a different coating that dissolves further down, in the lower small intestine. This creates two distinct peaks of the drug in your bloodstream rather than the single spike you get from older PPIs like lansoprazole or omeprazole. The result is a longer window of acid suppression from a single capsule.
For comparison, lansoprazole reaches its peak blood concentration in about 1.7 hours and has a half-life of roughly 1.5 hours, meaning it’s mostly cleared from your system within a few hours. Dexilant’s dual-peak profile maintains therapeutic drug levels for a significantly longer stretch. This extended action is the core clinical selling point, and the complex manufacturing process behind it is difficult and expensive to replicate, which is exactly what keeps generic competition thin.
Why the Generic Isn’t Cheap Either
Patients often assume that once a generic exists, prices will plummet. That hasn’t happened with dexlansoprazole. The generic version costs between $668 and $1,074 for a 90-capsule supply, depending on the pharmacy. Per capsule, that’s roughly $7.43 to $11.94, compared to about $10.30 per capsule for the brand name. In some cases, the generic actually costs more than the brand.
Several factors explain this. First, the dual-release capsule is genuinely harder to manufacture than a standard delayed-release pill, so production costs are higher. Second, the number of companies making the generic remains small because many of the formulation patents are still active. Less competition among manufacturers means less downward pressure on price. Third, without robust competition, generic companies have little incentive to undercut each other aggressively. The price relief that patients see with generics for simpler drugs, where a dozen manufacturers compete and push the cost below a dollar per pill, simply hasn’t materialized here.
Insurance and Formulary Barriers
Even with insurance, Dexilant often comes with a high copay or isn’t covered at all. Most insurance formularies place it in a higher tier because cheaper PPIs like omeprazole and pantoprazole are available over the counter for a fraction of the cost. Insurers typically require “step therapy,” meaning you have to try and fail on one or two cheaper alternatives before they’ll approve coverage for Dexilant. If your plan does cover it, you may still face a specialty-tier copay of $50 to $100 or more per month.
This creates a frustrating situation for people whose reflux responds better to Dexilant’s longer-acting formulation. The drug works differently enough from standard PPIs that some patients genuinely do better on it, but insurers treat it as interchangeable with medications that cost 95% less.
Ways to Lower the Cost
Takeda offers a patient assistance program called Help At Hand for people who are uninsured or underinsured. Eligibility varies by medication, and the program isn’t available to everyone, but it’s worth checking if you’re paying out of pocket. Takeda also periodically offers savings cards that reduce copays for commercially insured patients.
Beyond manufacturer programs, a few practical options can help. Pharmacy discount tools like GoodRx or RxSaver sometimes offer prices well below the retail cash price. Asking your pharmacist to compare the brand and generic prices is also worthwhile, since the generic isn’t always cheaper at every pharmacy. If cost is the main barrier and your doctor prescribed Dexilant specifically for its longer action, ask whether taking a standard PPI twice daily (once in the morning, once before dinner) might approximate the same extended coverage. It’s not an identical approach, but for many patients it provides comparable acid control at a fraction of the price.
Mail-order pharmacies and 90-day supply programs through your insurer can also reduce the per-capsule cost, since bulk pricing tends to be more favorable. Some patients find that purchasing through Canadian or international pharmacies offers substantial savings, though this route involves regulatory gray areas and requires careful vetting of the pharmacy’s legitimacy.